Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.

[1]  A. Michalsen,et al.  Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.

[2]  I. Forgacs,et al.  Fecal M2‐pyruvate kinase (M2‐PK): A novel marker of intestinal inflammation , 2007, Inflammatory bowel diseases.

[3]  J. Stein,et al.  Prospective evaluation of faecal neutrophil‐derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin , 2007, Alimentary pharmacology & therapeutics.

[4]  E. Louis,et al.  Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level , 2007, Inflammatory bowel diseases.

[5]  D. Foell,et al.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome , 2007, Gut.

[6]  M. Plebani,et al.  Enzymes in feces: useful markers of chronic inflammatory bowel disease. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[7]  M. Plebani,et al.  Fecal Lactoferrin and Calprotectin After Ileocolonic Resection for Crohn’s Disease , 2007, Diseases of the colon and rectum.

[8]  N. Borruel,et al.  Fecal Excretion of Deoxyribonucleic Acid in Long‐term Follow‐up of Patients with Inactive Ulcerative Colitis , 2007, Inflammatory bowel diseases.

[9]  D. Martines,et al.  Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease , 2007, International Journal of Colorectal Disease.

[10]  J. Gisbert,et al.  Papel de los marcadores biológicos en la enfermedad inflamatoria intestinal , 2007 .

[11]  A. Darzi,et al.  Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy , 2007, The American Journal of Gastroenterology.

[12]  A. Gasbarrini,et al.  Fecal Calprotectin in First-Degree Relatives of Patients with Ulcerative Colitis , 2007, The American Journal of Gastroenterology.

[13]  W. Sandborn,et al.  Review article: biological activity markers in inflammatory bowel disease , 2006, Alimentary pharmacology & therapeutics.

[14]  A. Darzi,et al.  Diagnostic Precision of Anti-Saccharomyces cerevisiae Antibodies and Perinuclear Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease , 2006, The American Journal of Gastroenterology.

[15]  M. G. Sánchez,et al.  Precisión diagnóstica de la calprotectina fecal para predecir una colonoscopia patológica , 2006 .

[16]  L. Denson,et al.  Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease , 2006, Inflammatory bowel diseases.

[17]  Laurent Beaugerie,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.

[18]  B F Warren,et al.  European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis , 2006, Gut.

[19]  P. Rutgeerts,et al.  Laboratory markers in IBD: useful, magic, or unnecessary toys? , 2006, Gut.

[20]  T. Raivio,et al.  Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease , 2006, Scandinavian journal of gastroenterology.

[21]  A. Sodano,et al.  Combined Use of Noninvasive Tests is Useful in the Initial Diagnostic Approach to a Child with Suspected Inflammatory Bowel Disease , 2006, Journal of pediatric gastroenterology and nutrition.

[22]  A. Michalsen,et al.  Comparison of 4 Neutrophil‐Derived Proteins in Feces As Indicators of Disease Activity in Ulcerative Colitis , 2005, Inflammatory bowel diseases.

[23]  P. Rutgeerts,et al.  The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases , 2005, Nature Clinical Practice Gastroenterology &Hepatology.

[24]  M. Beattie,et al.  Faecal calprotectin in children with chronic gastrointestinal symptoms , 2005, Acta paediatrica.

[25]  D. Gaya,et al.  Faecal calprotectin in the assessment of Crohn's disease activity. , 2005, QJM : monthly journal of the Association of Physicians.

[26]  L. Hansson,et al.  Colorectal Inflammation is Well Predicted by Fecal Calprotectin in Children with Gastrointestinal Symptoms , 2005, Journal of pediatric gastroenterology and nutrition.

[27]  W. Sandborn,et al.  Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? , 2005, Gut.

[28]  M. Bottai,et al.  Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease , 2005, Gut.

[29]  P. Hellström,et al.  Technology Insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease , 2005, Nature Clinical Practice Gastroenterology &Hepatology.

[30]  R. D'Incà,et al.  The Role of Costimulatory Molecules CD80 and CD86 and IFNγ in the Pathogenesis of Ulcerative Colitis , 2004, Digestive Diseases and Sciences.

[31]  P. Rutgeerts,et al.  Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. , 2004, Gastrointestinal endoscopy.

[32]  H. Hanai,et al.  Relationship Between Fecal Calprotectin, Intestinal Inflammation, and Peripheral Blood Neutrophils in Patients with Active Ulcerative Colitis , 2004, Digestive Diseases and Sciences.

[33]  S. Dolwani,et al.  Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology , 2004, Alimentary pharmacology & therapeutics.

[34]  Paul Rutgeerts,et al.  C-Reactive Protein as a Marker for Inflammatory Bowel Disease , 2004, Inflammatory bowel diseases.

[35]  F. Manguso,et al.  Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[36]  S. Dolwani,et al.  Faecal calprotectin: a new marker for Crohn's disease? , 2004, Annals of clinical biochemistry.

[37]  A. Poullis,et al.  Bowel Inflammation as Measured by Fecal Calprotectin , 2004, Cancer Epidemiology Biomarkers & Prevention.

[38]  A. Røseth,et al.  Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease , 2004, Scandinavian journal of gastroenterology.

[39]  L. Hansson,et al.  Fecal Calprotectin Levels in Healthy Children Studied With an Improved Assay , 2003, Journal of pediatric gastroenterology and nutrition.

[40]  A. Røseth.  Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[41]  M. Bellini,et al.  Role of faecal calprotectin as non-invasive marker of intestinal inflammation. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[42]  D. Gudbjartsson,et al.  Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? , 2003, Gastroenterology.

[43]  G. Di Fede,et al.  Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. , 2003, Clinical chemistry.

[44]  M. Camilleri,et al.  Fecal Lactoferrin Is a Sensitive and Specific Marker in Identifying Intestinal Inflammation , 2003, American Journal of Gastroenterology.

[45]  A. Poullis,et al.  Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. , 2003, European journal of gastroenterology & hepatology.

[46]  D. Gaya,et al.  Faecal calprotectin: a bright future for assessing disease activity in Crohn's disease. , 2002, QJM : monthly journal of the Association of Physicians.

[47]  I. Forgacs,et al.  Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. , 2002, Gastroenterology.

[48]  D. Shreeve,et al.  Faecal calprotectin: a marker of inflammation throughout the intestinal tract , 2002, European journal of gastroenterology & hepatology.

[49]  S. Ghosh,et al.  Is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? , 2002 .

[50]  A. Poullis,et al.  Faecal markers in the assessment of activity in inflammatory bowel disease , 2002 .

[51]  A. Berstad,et al.  Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children , 2002, Acta paediatrica.

[52]  I. Bjarnason,et al.  Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma , 2001, Gut.

[53]  E. Husebye,et al.  Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm , 2001, American Journal of Gastroenterology.

[54]  I. Bjarnason,et al.  Non-invasive investigation of inflammatory bowel disease. , 2001, World journal of gastroenterology.

[55]  S. Bunn,et al.  Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. , 2001, Journal of pediatric gastroenterology and nutrition.

[56]  S. Bunn,et al.  Fecal Calprotectin as a Measure of Disease Activity in Childhood Inflammatory Bowel Disease , 2001, Journal of pediatric gastroenterology and nutrition.

[57]  I. Bjarnason,et al.  Fecal calprotectin as an index of intestinal inflammation. , 2001, Drugs of today.

[58]  B. Thjódleifsson,et al.  A simple method for assessing intestinal inflammation in Crohn's disease , 2000, Gut.

[59]  A. Zinsmeister,et al.  Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy , 2000, American Journal of Gastroenterology.

[60]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.

[61]  H. Schjønsby,et al.  Improved assay for fecal calprotectin. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[62]  B. Vainer,et al.  Established and emerging biological activity markers of inflammatory bowel disease. , 2000, The American journal of gastroenterology.

[63]  A. Røseth,et al.  High prevalence of NSAID enteropathy as shown by a simple faecal test , 1999, Gut.

[64]  D. Mabey,et al.  The effects of multiple doses of ivermectin on ocular onchocerciasis. A six-year follow-up. , 1996, Ophthalmology.

[65]  T. Meling,et al.  Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. , 1996, Scandinavian journal of gastroenterology.

[66]  R. Modigliani.  Endoscopic management of inflammatory bowel disease. , 1994, The American journal of gastroenterology.

[67]  B. Roald,et al.  Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? , 1993, Scandinavian journal of gastroenterology.

[68]  K. Pulford,et al.  Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. , 1993, Gut.

[69]  A. Røseth,et al.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. , 1992, Scandinavian journal of gastroenterology.

[70]  D. Rothenberger,et al.  Recurrence of Crohn's disease after resection , 1991, The British journal of surgery.

[71]  R. Modigliani,et al.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. , 1990, Gastroenterology.

[72]  J. Mate,et al.  [Role of biological markers in inflammatory bowel disease]. , 2007, Gastroenterologia y hepatologia.

[73]  F. Castiglione,et al.  The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. , 2006, European review for medical and pharmacological sciences.

[74]  J. Muntané,et al.  [Diagnostic value of fecal calprotectin in predicting an abnormal colonoscopy]. , 2006, Medicina clinica.

[75]  O. Mickisch,et al.  Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. , 2005, Clinical laboratory.

[76]  A. M. van den Neucker,et al.  Fecal calprotectin in healthy term and preterm infants. , 2004, Journal of pediatric gastroenterology and nutrition.

[77]  J. Mate,et al.  [The role of anti-neutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) in inflammatory bowel disease]. , 2003, Gastroenterologia y hepatologia.

[78]  J. Gisbert,et al.  Papel de los anticuerpos anticitoplasma de los neutrófilos (ANCA) y anti- Saccharomyces cerevisiae (ASCA) en la enfermedad inflamatoria intestinal , 2003 .

[79]  I. Arnott,et al.  Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? , 2002, Alimentary pharmacology & therapeutics.

[80]  A. Poullis,et al.  Review article: faecal markers in the assessment of activity in inflammatory bowel disease. , 2002, Alimentary pharmacology & therapeutics.

[81]  H. Verspaget,et al.  Faecal parameters in the assessment of activity in inflammatory bowel disease. , 1999, Scandinavian journal of gastroenterology. Supplement.

[82]  A. Røseth,et al.  Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. , 1999, Scandinavian journal of gastroenterology.

[83]  J. Jahnsen,et al.  Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. , 1997, Digestion.

[84]  S. Saverymuttu.  Clinical remission in Crohn's disease--assessment using faecal 111In granulocyte excretion. , 1986, Digestion.

[85]  Erik Carlsson,et al.  A methodologic study , 1977 .